EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

EU antitrust regulators are soliciting feedback from competitors and customers regarding Novo Holdings' proposed $16.5 ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Catalent Inc., a leading global contract development and manufacturing organization (CDMO), is known for its expertise in optimizing product development, launch, and full life-cycle supply for the ...